Correlation of MAGE-A tumor antigens and the efficacy of various chemotherapeutic agents in head and neck carcinoma cells

Hartmann, Stefan; Kriegebaum, Ulrike; Küchler, Nora; Brands, Roman C.; Linz, Christian; Kübler, Alexander C.; Müller‐Richter, Urs

doi:10.1007/s00784-013-0936-0

Cited by 22 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As described by their group, N0 cervical lymph node status was found more frequently in MAGE-A12-positive patients than that of the MAGE-negative controls. Furthermore, MAGA-A11 was reported to have a negative impact on treatment with cisplatin, 5-fluorouracil, paclitaxel and docetaxel (16). In the same study, MAGE-A5 was demonstrated to be associated with improved outcomes following paclitaxel therapy.…”

Section: Discussionmentioning

confidence: 83%

“…In addition, a previous study by our group identified a correlation between MAGE-A5 and -A8 expression and poorer responses to anti-epidermal growth factor receptor (EGFR) therapy in vitro (15). Of note, MAGE-A11 expression is also correlated with poorer responses to cisplatin, 5-fluorouracil, docetaxel and paclitaxel (16).…”

Section: Introductionmentioning

confidence: 84%

“…The protocol and quantification of MAGE-A expression by RT-qPCR was conducted as previously described by our group (15,16).…”

Section: Rna Isolation and Reverse Transcription-quantitative Polymermentioning

confidence: 99%

See 2 more Smart Citations

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer

et al. 2015

View full text Add to dashboard Cite

Abstract. Melanoma-associated antigen (MAGE) has been identified in a variety of types of cancer. The expression of several MAGE subgroups is correlated with poor prognosis and chemotherapeutic resistance. One target of chemotherapeutic treatment in head and neck cancer is the epidermal growth factor receptor (EGFR). The efficacy of tyrosine kinase inhibitors (TKI) in the context of melanoma-associated antigens is discussed in the present study. Five human squamous cell carcinoma cell lines were treated with the EGFR TKIs, erlotinib and gefitinib. The efficacy of these agents was measured using a crystal violet assay. Furthermore, the expression levels of MAGE-A1, -A5, -A8, -A9, -A11 and -A12 were determined by reverse transcription-quantitative polymerase chain reaction. The association between TKI efficacy and MAGE-A expression was analyzed by linear regression. The cell lines revealed inhomogeneous expression patterns for the MAGE-A subgroups. Four of the five cell lines demonstrated a good response to erlotinib and gefitinib. However, treatment with erlotinib induced better results than those of gefitinib, and revealed a concentration-dependent effect. The expression of MAGE-A5 and -A11 were significantly correlated with lower efficacy of erlotinib and gefitinib. By contrast, MAGE-A12 was associated with a superior response to these two drugs. One cell line, which expressed all investigated MAGE-A subgroups, was entirely resistant to the two TKIs. These results revealed a notable correlation between MAGE-A5 and -A11 and lower efficacy of EGFR TKIs. Pretreatment analysis of MAGE-A status may therefore aid improvement of chemoprevention using erlotinib and gefitinib in head and neck cancer.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 84%

See 1 more Smart Citation

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Cisplatin is a broad-spectrum anticarcinogen, which is also used in combination with hyperthermia (Issels, 2008). The tumor cell inhibition of high doses of cisplatin (80 and 120 μg/ml) at 24 h in vitro is above 80% (Hartmann et al, 2014;Su et al, 2012). Anucleated erythrocytes are little damaged by cisplatin in theory because the key molecular target of cisplatin is eukaryotic DNA (Issels, 2008).…”

Section: Discussionmentioning

confidence: 99%

Cisplatin combined with hyperthermia kills HepG2 cells in intraoperative blood salvage but preserves the function of erythrocytes

Yang

Tang

Liu

et al. 2015

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:The safe use of intraoperative blood salvage (IBS) in cancer surgery remains controversial. Here, we investigated the killing effect of cisplatin combined with hyperthermia on human hepatocarcinoma (HepG2) cells and erythrocytes from IBS in vitro. HepG2 cells were mixed with concentrated erythrocytes and pretreated with cisplatin (50, 100, and 200 μg/ml) alone at 37 °C for 60 min and cisplatin (25, 50, 100, and 200 μg/ml) combined with hyperthermia at 42 °C for 60 min. After pretreatment, the cell viability, colony formation and DNA metabolism in HepG2 and the Na + -K + -ATPase activity, 2,3-diphosphoglycerate (2,3-DPG) concentration, free hemoglobin (Hb) level, osmotic fragility, membrane phosphatidylserine externalization, and blood gas variables in erythrocytes were determined. Pretreatment with cisplatin (50, 100, and 200 μg/ml) combined with hyperthermia (42 °C) for 60 min significantly decreased HepG2 cell viability, and completely inhibited colony formation and DNA metabolism when the HepG2 cell concentration was 5×10 4 ml −1 in the erythrocyte (P<0.01). Erythrocytic Na + -K + -ATPase activity, 2,3-DPG level, phosphatidylserine externalization, and extra-erythrocytic free Hb were significantly altered by hyperthermia plus high concentrations of cisplatin (100 and 200 μg/ml) (P<0.05), but not by hyperthermia plus 50 μg/ml cisplatin (P>0.05). In conclusion, pretreatment with cisplatin (50 μg/ml) combined with hyperthermia (42 °C) for 60 min effectively eliminated HepG2 cells from IBS but did not significantly affect erythrocytes in vitro.

show abstract

“…High expression levels of MAGE-A in HNSCC tumors are predictive for a poor overall survival (15,16). The correlation between the expression of a particular MAGE-A subgroup and the treatment efficiency of chemotherapeutic drugs was reported by our group earlier (17)(18)(19). Han et al showed that there is a significant correlation between high MAGE-A9 expression levels and a low overall survival in laryngeal squamous cell carcinoma patients (20).…”

Section: Introductionmentioning

confidence: 96%

MAGE-A9 in head and neck cancer: Prognostic value and preclinical findings in the context of irradiation

et al. 2018

View full text Add to dashboard Cite

Abstract. Radiotherapy alone, or as an addition to surgery is important for the treatment of head and neck squamous cell carcinoma (HNSCC). In addition to their expression in germ cells, melanoma associated antigens-A (MAGE-A) are only expressed in malignant tissue. Notably, there is a known correlation between MAGE-A9 expression and poor prognosis in HNSCC patients. However, current knowledge regarding the function of MAGE-A9 expression, particularly in the context of irradiation, is limited. MAGE-A9 expression in 37 oral squamous cell carcinoma patents was immunohistochemically determined and analyzed for overall survival by the Kaplan-Meier log-rank test. Next, the expression of MAGE-A9 was determined by reverse transcription-quantitative polymerase chain reaction in HNSCC cell lines prior to and following irradiation with 2 Gray. The radiosensitivity of each cell line was determined using a clonogenic survival assay. There was a significantly (P=0.0468) longer overall survival in patients with a low level of MAGE-A9 expression. The median overall survival in patients with high MAGE-A9 expression was 47% compared to 73% in the group with low MAGE-A9 expression. The cell lines revealed a distinct expression pattern of MAGE-A9. Following irradiation of the cell lines, a significant enhancement of MAGE-A9 mRNA expression levels was observed. The most prominent alteration in MAGE-A9 expression was observed in the most radioresistant cell line. A high MAGE-A9 expression level correlates significantly with lower overall survival in HNSCC patients. Additionally, irradiation increased the MAGE-A9 mRNA levels in all five HNSCC cell lines, and the most resistant cell line demonstrated the greatest increase in MAGE-A9 expression following irradiation.

show abstract

Correlation of MAGE-A tumor antigens and the efficacy of various chemotherapeutic agents in head and neck carcinoma cells

Abstract: These findings could affect the antineoplastic treatment of patients with MAGE-A11-positive tumors.

Cited by 22 publications

References 27 publications

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer

Cisplatin combined with hyperthermia kills HepG2 cells in intraoperative blood salvage but preserves the function of erythrocytes

MAGE-A9 in head and neck cancer: Prognostic value and preclinical findings in the context of irradiation

Contact Info

Product

Resources

About